HUTCHMED (China) Limited

NasdaqGS:HCM Stock Report

Market Cap: US$2.6b

HUTCHMED (China) Balance Sheet Health

Financial Health criteria checks 4/6

HUTCHMED (China) has a total shareholder equity of $752.0M and total debt of $82.1M, which brings its debt-to-equity ratio to 10.9%. Its total assets and total liabilities are $1.3B and $508.9M respectively.

Key information

10.9%

Debt to equity ratio

US$82.10m

Debt

Interest coverage ration/a
CashUS$803.51m
EquityUS$752.02m
Total liabilitiesUS$508.85m
Total assetsUS$1.26b

Recent financial health updates

No updates

Recent updates

Hutchmed Growing Sales By 64% In H1 2024

Aug 09

Hutchmed Is Turning Profitable

Mar 20

Hutchmed begins dosing in phase 2/3 trial of sovleplenib for red blood cell disorder

Oct 10

Hutchmed, Inmagene begin dosing in phase 1 trial of potential autoimmune disease drug IMG-004

Aug 09

Hutchmed begins dosing in mid-stage study of tazemetostat in blood cancer subtype

Aug 01

Hutchmed begins dosing in early-stage study of cancer drug HMPL-A83

Jul 15

Hutchmed, Inmagene begin dosing in early-stage study of IMG-007 for eczema

Jul 06

Hutchmed Roils Markets With Changing Of Its Guard, U.S. Delisting Threat

Mar 11

Financial Position Analysis

Short Term Liabilities: HCM's short term assets ($1.0B) exceed its short term liabilities ($373.3M).

Long Term Liabilities: HCM's short term assets ($1.0B) exceed its long term liabilities ($135.6M).


Debt to Equity History and Analysis

Debt Level: HCM has more cash than its total debt.

Reducing Debt: HCM's debt to equity ratio has increased from 0.2% to 10.9% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HCM has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if HCM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 15:38
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

HUTCHMED (China) Limited is covered by 46 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jiangqiao TongBOCI Research Ltd.
Linda LuBOCI Research Ltd.
Alec StranahanBofA Global Research